181 related articles for article (PubMed ID: 36774237)
81. Neurofibromatosis type 1.
Boyd KP; Korf BR; Theos A
J Am Acad Dermatol; 2009 Jul; 61(1):1-14; quiz 15-6. PubMed ID: 19539839
[TBL] [Abstract][Full Text] [Related]
82. Case report of ascending colon cancer and multiple jejunal GISTs in a patient with neurofibromatosis type 1 (NF1).
Shang L; Fang Z; Liu J; Du F; Jing H; Xu Y; Dong K; Zhang X; Wu H; Jing C; Li L
BMC Cancer; 2019 Dec; 19(1):1196. PubMed ID: 31805970
[TBL] [Abstract][Full Text] [Related]
83. The spectrum of NF1 mutations in Korean patients with neurofibromatosis type 1.
Jeong SY; Park SJ; Kim HJ
J Korean Med Sci; 2006 Feb; 21(1):107-12. PubMed ID: 16479075
[TBL] [Abstract][Full Text] [Related]
84. The promise of signal transduction in genetically driven sarcomas of the nerve.
Kim A; Pratilas CA
Exp Neurol; 2018 Jan; 299(Pt B):317-325. PubMed ID: 28859862
[TBL] [Abstract][Full Text] [Related]
85. Pathogenic Mutations Associated with Legius Syndrome Modify the Spred1 Surface and Are Involved in Direct Binding to the Ras Inactivator Neurofibromin.
Führer S; Tollinger M; Dunzendorfer-Matt T
J Mol Biol; 2019 Sep; 431(19):3889-3899. PubMed ID: 31401120
[TBL] [Abstract][Full Text] [Related]
86. Ras-Mek-Erk signaling regulates Nf1 heterozygous neointima formation.
Stansfield BK; Bessler WK; Mali R; Mund JA; Downing BD; Kapur R; Ingram DA
Am J Pathol; 2014 Jan; 184(1):79-85. PubMed ID: 24211110
[TBL] [Abstract][Full Text] [Related]
87. NF1 and Neurofibromin: Emerging Players in the Genetic Landscape of Desmoplastic Melanoma.
Mahalingam M
Adv Anat Pathol; 2017 Jan; 24(1):1-14. PubMed ID: 27941538
[TBL] [Abstract][Full Text] [Related]
88. Translationally controlled tumor protein is a novel biological target for neurofibromatosis type 1-associated tumors.
Kobayashi D; Hirayama M; Komohara Y; Mizuguchi S; Wilson Morifuji M; Ihn H; Takeya M; Kuramochi A; Araki N
J Biol Chem; 2014 Sep; 289(38):26314-26326. PubMed ID: 25092287
[TBL] [Abstract][Full Text] [Related]
89. Translating current basic research into future therapies for neurofibromatosis type 1.
Brosseau JP; Liao CP; Le LQ
Br J Cancer; 2020 Jul; 123(2):178-186. PubMed ID: 32439933
[TBL] [Abstract][Full Text] [Related]
90. The neurofibromatosis type 1 gene product neurofibromin enhances cell motility by regulating actin filament dynamics via the Rho-ROCK-LIMK2-cofilin pathway.
Ozawa T; Araki N; Yunoue S; Tokuo H; Feng L; Patrakitkomjorn S; Hara T; Ichikawa Y; Matsumoto K; Fujii K; Saya H
J Biol Chem; 2005 Nov; 280(47):39524-33. PubMed ID: 16169856
[TBL] [Abstract][Full Text] [Related]
91. Neurofibromatosis type 1.
Cimino PJ; Gutmann DH
Handb Clin Neurol; 2018; 148():799-811. PubMed ID: 29478615
[TBL] [Abstract][Full Text] [Related]
92. An update on the central nervous system manifestations of neurofibromatosis type 1.
Nix JS; Blakeley J; Rodriguez FJ
Acta Neuropathol; 2020 Apr; 139(4):625-641. PubMed ID: 30963251
[TBL] [Abstract][Full Text] [Related]
93. Structural basis of activation of the tumor suppressor protein neurofibromin.
Chaker-Margot M; Werten S; Dunzendorfer-Matt T; Lechner S; Ruepp A; Scheffzek K; Maier T
Mol Cell; 2022 Apr; 82(7):1288-1296.e5. PubMed ID: 35353986
[TBL] [Abstract][Full Text] [Related]
94. Pulmonary hypertension in patients with neurofibromatosis type I.
Montani D; Coulet F; Girerd B; Eyries M; Bergot E; Mal H; Biondi G; Dromer C; Hugues T; Marquette C; O'Connell C; O'Callaghan DS; Savale L; Jaïs X; Dorfmüller P; Begueret H; Bertoletti L; Sitbon O; Bellanné-Chantelot C; Zalcman G; Simonneau G; Humbert M; Soubrier F
Medicine (Baltimore); 2011 May; 90(3):201-211. PubMed ID: 21512413
[TBL] [Abstract][Full Text] [Related]
95. [Developmental manifestation in children with neurofibromatosis type 1].
Cohen R; Shuper A
Harefuah; 2010 Jan; 149(1):49-52, 61. PubMed ID: 20422842
[TBL] [Abstract][Full Text] [Related]
96. Atypical hematologic and renal manifestations in neurofibromatosis type I: coincidence or pathophysiological link?
Van-Gils J; Harambat J; Jubert C; Vidaud D; Llanas B; Perel Y; Lacombe D; Goizet C
Eur J Med Genet; 2014; 57(11-12):639-42. PubMed ID: 25234363
[TBL] [Abstract][Full Text] [Related]
97. Neurofibromin (Nf1) is required for skeletal muscle development.
Kossler N; Stricker S; Rödelsperger C; Robinson PN; Kim J; Dietrich C; Osswald M; Kühnisch J; Stevenson DA; Braun T; Mundlos S; Kolanczyk M
Hum Mol Genet; 2011 Jul; 20(14):2697-709. PubMed ID: 21478499
[TBL] [Abstract][Full Text] [Related]
98. Past, Present, and Future Therapeutic Strategies for NF-1-Associated Tumors.
Na B; Shah SR; Vasudevan HN
Curr Oncol Rep; 2024 Jun; 26(6):706-713. PubMed ID: 38709422
[TBL] [Abstract][Full Text] [Related]
99. Generation of a human iPSC line CIPi004-A from a patient with neurofibromatosis type 1 and epilepsy harboring a heterozygous mutation in NF1 gene.
Wu F; Ji X; Gao Y; Liu W; Lu Y; Yang A; Wang J; Chen Q; Zhang X
Stem Cell Res; 2024 Jun; 77():103444. PubMed ID: 38761686
[TBL] [Abstract][Full Text] [Related]
100. NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.
House RRJ; Tovar EA; Redlon LN; Essenburg CJ; Dischinger PS; Ellis AE; Beddows I; Sheldon RD; Lien EC; Graveel CR; Steensma MR
Mol Metab; 2024 Feb; 80():101876. PubMed ID: 38216123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
